New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For DELL;ADNC;MRK;TSN;CTRP;GDOT;VVUS;NFLX;MCK;MAT;LTM;ALKS;ELN From The Last 14 Days
Check below for free stories on DELL;ADNC;MRK;TSN;CTRP;GDOT;VVUS;NFLX;MCK;MAT;LTM;ALKS;ELN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | 4 | 5 | all recent news | >>
April 17, 2014
16:35 EDTALKSAlkermes recent pullback a buying opportunity, says Leerink
Leerink does not expect any surprises when Alkermes reports Q1 results and views the recent pullback in shares as a buying opportunity. The firm reiterates an Outperform rating on the stock with a $66 price target.
16:31 EDTNFLXOn The Fly: Closing Wrap
Subscribe for More Information
14:55 EDTNFLXNetflix rallies after upgrade, Vodafone content deal talks
Subscribe for More Information
13:50 EDTMRKFDA approves Ragwitek for short ragweed pollen allergies
Subscribe for More Information
12:59 EDTMATMattel falls after reporting lower Q1 international, North American sales
Subscribe for More Information
12:46 EDTNFLXVodafone, Netflix in talks on content deal, Bloomberg says
Vodafone (VOD) is in early stage talks with Netflix (NFLX) to offer Vodafone customers free access access to its streaming service for a period of time, according to Bloomberg, citing three people familiar with the talks. Reference Link
10:17 EDTNFLXStocks with call strike movement; FB NFLX
Subscribe for More Information
09:59 EDTNFLXOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:35 EDTNFLXActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL GOOGL GOOG NFLX TSLA AMZN GOLG NOV AA IBM
09:01 EDTMATMattel sees FY14 CapEx $230M-$240M
Subscribe for More Information
08:58 EDTMATOn The Fly: Pre-market movers
Subscribe for More Information
08:38 EDTMATMattel maintains FY14 gross margin view within low-to-mid 50% range
Subscribe for More Information
06:58 EDTNFLXNetflix, Comcast deal questioned by senator, NY Post says
Subscribe for More Information
06:18 EDTMATMattel CEO: global retail environment in Q1 "challenging"
Subscribe for More Information
06:17 EDTMATMattel reports Q1 international sales down 7%
Q1 international sales inlcude a 1% unfavorable impact from changes in currency exchange rates.
06:16 EDTMATMattel reports Q1 North American sales down 2%
Subscribe for More Information
06:04 EDTMATMattel reports Q1 EPS (3c), consensus 9c
Subscribe for More Information
05:33 EDTNFLXNetflix upgraded to Outperform from Sector Perform at Pacific Crest
Pacific Crest upgraded its rating on Netflix (NFLX) to Outperform from Sector Perform on expectations the company's international growth will accelerate meaningfully over the next 18 months. The firm has a $500 price target for shares.
April 16, 2014
16:00 EDTNFLXOptions Update; April 16, 2014
Subscribe for More Information
15:17 EDTMATNotable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's market open, with earnings consensus, include General Electric (GE), consensus 32c; Philip Morris (PM), consensus $1.16; Schlumberger (SLB), consensus $1.20; PepsiCo (PEP), consensus 75c; Union Pacific (UNP), consensus $2.37; UnitedHealth (UNH), consensus $1.09; Honeywell (HON), consensus $1.26; Goldman Sachs (GS), consensus $3.44; du Pont (DD), consensus $1.59; Morgan Stanley (MS), consensus 60c; Danaher (DHR), consensus 80c; BlackRock (BLK), consensus $4.14; Blackstone (BX), consensus 55c; Chipotle Mexican Grill (CMG), consensus $2.86; Mattel (MAT), consensus 9c; Snap-on (SNA), consensus $1.54; AutoNation (AN), consensus 74c.
13:00 EDTNFLXNetflix to launch Germany service in September, GigaOM says
Subscribe for More Information
12:16 EDTTSNPost likely to beat out Tyson for Michael Foods, WSJ says
Subscribe for More Information
12:08 EDTNFLXStocks with call strike movement; TWTR NFLX
Subscribe for More Information
10:16 EDTNFLXNetflix April weekly volatility elevated at 106 into Q1 and outlook
Subscribe for More Information
09:36 EDTNFLXActive equity options trading on open
Subscribe for More Information
07:53 EDTNFLXNetflix Q1 results should be solid, says RW Baird
Baird expects Netflix to report solid Q1 results and remains bullish on the company's medium and long-term opportunities. The firm, however, does not expect to see meaningful upside to subscriber growth due to seasonality. Baird keeps an Outperform rating and $470 price target on the stock.
06:27 EDTNFLXNBCUniversal planning digital video push
Subscribe for More Information
April 15, 2014
13:14 EDTNFLXNetflix volatility elevated up as shares pullback to six-month low into Q1
Subscribe for More Information
10:55 EDTCTRPCtrip.com price target raised to $53 from $39 at Piper Jaffray
Subscribe for More Information
08:23 EDTMRKLeerink's pharma and biotech analysts hold an analyst/industry conference call
Subscribe for More Information
08:19 EDTMRKLeerink's pharma and biotech analysts hold an analyst/industry conference call
Subscribe for More Information
08:10 EDTMATMattel April volatility elevated at 60 into Q1 and outlook
Subscribe for More Information
06:32 EDTMRKPatients paying much more for specialty drugs, NY Times says
The amount that patients with certain diseases must pay for specialty drugs has increased significantly, a research firm reported, according to The New York Times. Meanwhile, consumers' use of health care increased in 2013 for the firm time in three years, the newspaper quoted the firm, the IMS Institute for Healthcare Informatics, as saying. Publicly traded drug makers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Publicly traded health insurers include AMERIGROUP (AGP), Aetna (AET), Centene (CNC), Cigna (CI), Health Net (HNT), Healthspring (HS), Humana (HUM), Molina Healthcare (MOH), UnitedHealth (UNH), WellCare (WCG) and WellPoint (WLP).Reference Link
April 14, 2014
18:00 EDTMRKU.S. FDA approves Merck's GRASTEK
Subscribe for More Information
13:19 EDTNFLXNetflix's streaming speeds on Comcast jumped, The Verge reports
Subscribe for More Information
09:36 EDTNFLXActive equity options trading on open
Subscribe for More Information
06:08 EDTMRKMerck volatility elevated into Q1 and outlook
Subscribe for More Information
April 11, 2014
15:44 EDTTSNTyson, Post final contenders to buy Michael Foods, Reuters says
Michael Foods, the egg and dairy products maker that has been put up for sale by Goldman Sachs' (GS) private equity arm, is evaluating binding bids from Tyson (TSN) and Post (POST) and is near a deal to be sold to one of the two for close to $2.5B, according to Reuters, citing people familiar with the matter. Reference Link
10:56 EDTCTRPOptions with increasing implied volatility: CYTK VJET DATA GRPN CTRP
10:29 EDTCTRPRumor: Ctrip.com moves up on renewed takeover chatter
Subscribe for More Information
09:37 EDTNFLXActive equity options trading on open
Subscribe for More Information
07:06 EDTVVUSVIVUS announces avanafil clinical data presentation
Subscribe for More Information
05:22 EDTMRKMerck says Hepatitis C combination therapy shows antiviral activity
Subscribe for More Information
April 10, 2014
17:44 EDTMRKMerck stock could return 20%, Barron's says
Subscribe for More Information
16:00 EDTNFLXOptions Update; April 10, 2014
Subscribe for More Information
12:52 EDTNFLXCarl Icahn says eBay separation 'not if but when'
Subscribe for More Information
10:00 EDTNFLX, ALKSOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:37 EDTMRKActive equity options trading on open
Active equity options trading on open according to Track Data: SIRI RAD AAPL AMZN AA FB TSLA MRK CVX C
09:21 EDTMRKOn The Fly: Pre-market Movers
Subscribe for More Information
08:44 EDTNFLXNetflix upgraded to Buy from Hold at Hudson Square
Subscribe for More Information
08:03 EDTMRKXencor Merck receives milestone payment from Merck for using XmAb antibody
Xencor (XNCR) announced that the company has received a milestone payment from Merck (MRK), through a subsidiary, triggered by the initiation of a Phase 1 clinical trial for an undisclosed biologic drug candidate that uses Xencor's XmAb antibody engineering intellectual property. Under the terms of the agreement signed in June 2013, Xencor granted Merck a non-exclusive license to certain Xencor patents for use in an undisclosed product, as well as an option to license the same intellectual property for future products. Xencor received an upfront payment and continues to receive annual maintenance fees. Xencor is also eligible to receive milestone payments associated with the successful development of Merck product candidates, as well as royalties on sales of any potential products that may result from this agreement.
05:55 EDTALKSAlkermes upgraded to Buy from Neutral at Mizuho
Subscribe for More Information
05:27 EDTMRKMerck announces data from C-WORTHy study
Merck announced additional data from the ongoing C-WORTHy study, a multi-arm Phase 2 clinical trial evaluating the efficacy and safety of a once-daily, all-oral regimen combining MK-5172, an investigational hepatitis C virus, or HCV, NS3/4A protease inhibitor, and MK-8742, an investigational HCV NS5A replication complex inhibitor, among patients with chronic HCV Genotype 1 infection, or GT1. In an interim analysis of treatment-na´ve, non-cirrhotic patients administered a 12-week regimen of MK-5172/MK-8742, with and without ribavirin, or RBV, a sustained viral response, or SVR, was observed in 98% of patients administered MK-5172/MK-8742 alone and 94% in those administered MK-5172/MK-8742 plus RBV.
April 9, 2014
12:07 EDTTSNU.S. red meat, poultry production forecast lowered
Subscribe for More Information
11:43 EDTMRKGilead defended by analysts after recent pullback
Subscribe for More Information
10:18 EDTCTRPCtrip.com falls in early trading, levels to watch
Subscribe for More Information
09:03 EDTCTRPCtrip.com volatility increased on deal speculation
Ctrip.com April call option implied volatility is at 69, May is at 72, June is at 62; compared to its 26-week average of 56 according to Track Data, suggesting large near term price movement a day after partnership possibilities and merger speculation.
08:31 EDTCTRP, CTRPSpeculation of Baidu interest in Ctrip.com logical, says CLSA
Subscribe for More Information
07:49 EDTNFLXAmazon unclear about limits of Fire TV voice search, BI says
Amazon (AMZN) claimed to have addressed user annoyances when it detailed the voice search features of its new Fire TV system last week, but the company was unclear about the fact that voice searches only present results from Amazon's Instant Video library and Vevo and exclude other services like Netflix (NFLX), said Business Insider. The company also was not upfront about the way voice searches are saved as recordings of users' voices, the report added. Reference Link
07:49 EDTALKSAlkermes price target raised to $66 from $60 at Leerink
Subscribe for More Information
07:23 EDTMRKEuropean Association for the Study of the Liver to hold annual meeting
Subscribe for More Information
07:15 EDTNFLXJPMorgan sees opportunities in Internet stocks after pullback
JPMorgan believes the recent sell-off in Internet stocks has created opportunities in companies it feels has strong fundamentals, namely Facebook (FB), Priceline (PCLN), Netflix (NFLX) and Pandora (P).
07:09 EDTMRKReckitt Benckiser may be frontrunner for Merck unit, Bloomberg reports
Subscribe for More Information
06:01 EDTNFLXRovi sell-off on patent ruling a buying opportunity, says Piper Jaffray
Subscribe for More Information
April 8, 2014
16:21 EDTNFLX, CTRPOn The Fly: Closing Wrap
Subscribe for More Information
16:01 EDTNFLXApple Netflix Citigroup Tesla Banco Santander Alcoa
Subscribe for More Information
14:43 EDTALKSAlkermes price target rasied to $66 from $60 at Leerink
12:12 EDTCTRPOn The Fly: Midday Wrap
Subscribe for More Information
11:48 EDTGDOTGreen Dot shares recommended at BTIG
BTIG believes Green Dot shares are poised to rebound and recommends purchase at current levels. Shares are Buy rated with a $31 price target.
11:03 EDTMRK, VVUSPiper Jaffray's biopharm analyst holds an analyst/industry conference call
Biopharm Analyst Schimmer discusses PCSK9 Inhibitors and other atherosclerosis approaches on an Analyst/Industry conference call. Relevant companies AEGR, ALNY, AMGN, ARNA, AZN, BMY, CBST, LLY, ESPR, GSK, ICPT, ISIS, MNKD, MRK, OREX, PFE, REGN, RHHBY, SNY and VVUS may be included on the Analyst/Industry conference call to be held on April 10 at 3 pm.
10:51 EDTCTRPCtrip, Qunar rise after Bloomberg says travel sites in deal talks
Subscribe for More Information
10:18 EDTCTRPCtrip.com May volatility elevated at 74
Ctrip.com April call option implied volatility is at 69, May is at 74, June is at 63; compared to its 26-week average of 56 according to Track Data, suggesting large near term price movement.
09:35 EDTNFLXActive equity options trading on open
Subscribe for More Information
09:09 EDTCTRPOn The Fly: Pre-market Movers
HIGHER: BioScrip (BIOS), up 6.7% after stock was named as a stock pick and a potential takeover target by Oscar Schafer while speaking on CNBC... Nokia (NOK), up 5% after deal to sell substantially all of its Devices & Services business to Microsoft (MSFT) receives regulatory approval in China... Ctrip.com (CTRP), up 4.6% after Bloomberg said, citing sources, that the company is in talks with Baidu-controlled (BIDU) Qunar (QUNR) about a partnership or a potential merger... Plug Power (PLUG), up 4.6% after CEO discusses plan to expand fuel cells to trucks in interview... FireEye (FEYE), up 2.5% following upgrade at Wedbush... Twitter (TWTR), up 2% following initiation of coverage with a Buy rating at at Janney Capital... Nike (NKE), up 1.75% after upgraded at Stifel. LOWER: Gigamon (GIMO), down 23% after lowering revenue outlook, shares downgraded at Pacific Crest... LivePerson (LPSN), down 3% after announcing resignation of EVP, Worldside Sales, shares downgraded at Benchmark... Cisco (CSCO), down 0.5% following downgrade to Hold from Buy at Wunderlich.
09:00 EDTALKSAlkermes rises 7.4%
Alkermes is up 7.4%, or $3.03, to $44.13
07:47 EDTALKSAlkermes to host conference call
Subscribe for More Information
07:28 EDTNFLXFour Internet stocks attractive after pullbacks, says Stifel
Subscribe for More Information
07:22 EDTCTRPQunar, Ctrip.com in talks on potential merger, Bloomberg says
Chinese travel websites Qunar (QUNR) and Ctrip.com (CTRP) are in talks on a range of possibilities, from a partnership to a full merger, according to Bloomberg, citing two people with direct knowledge of the talks. Qunar, which went public last year in the U.S., is majority owned by Chinese search giant Baidu (BIDU), which recently had over 58% of voting power via its stake. Reference Link
07:04 EDTALKSAlkermes announces phase 3 'positive' results from aripiprazole lauroxil study
Alkermes announced "positive" topline results from a randomized, double-blind, placebo-controlled phase 3 clinical trial of aripiprazole lauroxil in patients with schizophrenia. Patients treated once monthly with either 441 mg or 882 mg of aripiprazole lauroxil demonstrated statistically significant reductions from baseline in Positive and Negative Syndrome Scale total scores at week 12, compared to placebo, which was the prespecified primary endpoint in the study. Based on the positive results from this phase 3 study, Alkermes plans to submit a New Drug Application to the U.S. Food and Drug Administration in 3Q14. In addition to meeting the prespecified primary efficacy endpoint, the study also met the prespecified key secondary endpoint of improvement on the Clinical Global Impression-Improvement scale versus placebo at week 12. Aripiprazole lauroxil was generally well tolerated in the phase 3 study, and the safety profile of aripiprazole lauroxil was similar to that reported with oral aripiprazole. The most common adverse events in the study were insomnia, akathisia and headache. Alkermes will present data from the phase 3 study at an upcoming medical meeting and submit the results for publication in a peer-reviewed journal.
05:49 EDTCTRPStocks with implied volatility movement; CTRP GMCR
Subscribe for More Information
April 7, 2014
16:01 EDTNFLXOptions Update; April 7, 2014
Subscribe for More Information
10:00 EDTMATOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
10:00 EDTNFLXOn The Fly: Analyst Upgrade Summary
Agios Pharmaceuticals (AGIO) upgraded to Overweight from Neutral at JPMorgan... Alcoa (AA) upgraded to Hold from Sell at Deutsche Bank... Align Technology (ALGN) upgraded to Outperform from Market Perform at Barrington... Analog Devices (ADI) upgraded to Neutral from Sell at Goldman... B&G Foods (BGS) upgraded to Outperform from Sector Perform at RBC Capital... Citigroup (C) upgraded to Neutral from Underweight at HSBC... Intel (INTC) upgraded to Outperform from Sector Perform at Pacific Crest... JetBlue (JBLU) upgraded to Neutral from Sell at Goldman... Kindred Healthcare (KND) upgraded to Outperform from Sector Perform at RBC Capital... Lennox (LII) upgraded to Outperform from Market Perform at Wells Fargo... Newmont Mining (NEM) upgraded to Hold from Sell at Deutsche Bank... PBF Energy (PBF) upgraded to Buy from Neutral at Citigroup... Renasant (RNST) upgraded to Outperform from Market Perform at Raymond James... Select Medical (SEM) upgraded to Outperform from Sector Perform at RBC Capital... Ultra Petroleum (UPL) upgraded to Outperform from Market Perform at Raymond James... Under Armour (UA) upgraded to Buy from Neutral at Sterne Agee... Hercules Technology (HTGC) upgraded to Buy from Hold at Sandler ONeill... Standard Pacific (SPF) upgraded to Outperform from Market Perform at Raymond James... Yelp (YELP) upgraded to Outperform from Perform at Oppenheimer... Netflix (NFLX) upgraded to Outperform from Perform at Oppenheimer... Pandora (P) upgraded to Outperform from Neutral at Wedbush.
09:34 EDTNFLXActive equity options trading on open
Subscribe for More Information
09:10 EDTMATOn The Fly: Pre-market Movers
HIGHER: Questcor (QCOR), up 27% after agreeing to be bought by Mallinckrodt (MNK) for cash, stock valued at $86.10 per Questcor share... Agios Pharmaceuticals (AGIO), up 25% after program shows "promising clinical activity" for advanced blood cancers, shares upgraded at JPMorgan... Vocus (VOCS), up 47% after agreeing to be acquired by GTCR for $446.5M, or $18.00 per share... Pandora (P), up 1.3% following upgrade at Wedbush. LOWER: MannKind (MNKD), down 13% after announcing FDA extension of PDUFA date for Afrezza... American Eagle (AEO), down 2.2% following downgrade at Cowen... Pfizer (PFE), down 2.8% after announcing data for palbociclib in metastatic breast cancer... Mattel (MAT), down 3% following downgrade at BMO Capital... WWE (WWE), down 1.2% after cautious mention in Barron's, company announcing WrestleMania 30 grossed $10.9M.
09:04 EDTMCKMcKesson announces results of Celesio takeover offer
Subscribe for More Information
08:09 EDTMRKAlnylam's McSwiggen patent upheld in European opposition proceedings
Subscribe for More Information
07:27 EDTMRKAmerican Association of Cancer Research to hold annual meeting
Subscribe for More Information
07:09 EDTNFLXNetflix upgraded to Outperform from Perform at Oppenheimer
Oppenheimer upgraded its rating on Netflix (NFLX) shares to Outperform with a $419 price target citing the recent pullback in shares. Opco sees an attractive risk/reward profile at current share levels.
06:41 EDTNFLXMicrosoft pushes for programming to rival Amazon, Netflix, Bloomberg says
Subscribe for More Information
06:04 EDTMATMattel downgraded to Underperform from Market Perform at BMO Capital
BMO Capital downgraded Mattel citing earnings risk from cyclical declines in Barbie and Hot Wheels, disappointing performance in Max Steel and Ever After High, and deteriorating sales in Monster High. The analyst sees continued deterioration in earnings given weak mature markets, challenges in emerging markets, and lack of sales leverage and cost savings opportunities. Price target lowered to $33 from 40.
April 6, 2014
14:21 EDTNFLXYahoo plans to acquire bigger budget TV programming, WSJ says
Subscribe for More Information
13:37 EDTMRKMerck presents findings on clinical outcomes following treatment with MK-3475
Subscribe for More Information
<< 1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use